Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
about
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathwayAbiraterone in metastatic prostate cancer without previous chemotherapyCYP17 inhibitors in prostate cancer: latest evidence and clinical potentialProgress of molecular targeted therapies for prostate cancersAbiraterone in prostate cancer: a new angle to an old problemMedical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantAbiraterone in the treatment of metastatic castration-resistant prostate cancerPhase I trials of antitumour agents: fundamental conceptsUse of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancerQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesRecent progress in pharmaceutical therapies for castration-resistant prostate cancerProstate cancer: ESMO Consensus Conference Guidelines 2012Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and EnzalutamideCYP17 inhibitors for prostate cancer therapyAbiraterone and increased survival in metastatic prostate cancerPhase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utilityPhase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetateEmerging treatment options for patients with castration-resistant prostate cancer.Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promisesPractical guide to the use of abiraterone in castration resistant prostate cancer.A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer.Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Novel drugs targeting the androgen receptor pathway in prostate cancer.The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer.A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.The complex interplay between cholesterol and prostate malignancy.New hormonal therapies for castration-resistant prostate cancer.Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate CancerPhase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.Hormonal therapy in metastatic prostate cancer: current perspectives and controversiesBiomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan.Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancerOutsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancerEffects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone
P2860
Q24603649-A92ECF50-1F1A-4748-8730-B0D3111D552CQ24612084-09EE3167-C63C-428F-9E03-C28BDB9F2B0BQ26740070-6EA5EB12-140E-42CE-8832-4859E8E03E6BQ26823014-257AB33D-57D2-41DB-A30C-58CA000C8A72Q26828810-70971C0A-3AD8-411A-81AC-EA550B36D233Q26851177-CFAFABC7-21A1-4371-82D5-6E7132941630Q26853635-47C7121D-293A-4383-A352-C54F26833095Q26865346-1451362D-A195-4BA8-9679-B5DF6F5886FBQ26865701-6CD39569-C0F8-4CE9-805B-C7AFE5786977Q27011642-104D5A8F-22C3-4B2C-9B8D-6E0DD5F5F5BDQ27022567-C799C739-9775-4A93-8565-F8B00AE55057Q27022847-EB0C7B0D-8BC8-4A64-9E47-9C71E4B5965DQ28076820-E9289642-3E12-4308-8716-45865ECFA1D2Q28298818-73386F35-8A74-4F48-A9E9-F074888E857FQ29617512-BCB36DF8-0A3E-45AF-817F-19258A3FDC74Q33434141-9BFD5D9B-D74D-4029-AD8B-A20C03741E00Q33621403-3246EA27-82D9-4A91-9A06-892156491FB0Q33656820-AAD82474-2AE5-4C8C-9A67-2795571EB2AAQ33752605-469890E6-510C-420D-8C0B-14A4CE528F4CQ33770374-061E82BA-5EA0-41B6-8E9F-CC813727B855Q33958519-8C40BE98-5096-47B4-A4F3-32970F4D189BQ34002823-AA8AF11E-4ED7-4C36-84D8-FF8EEB98B76BQ34070638-0465E59A-0194-420B-804C-D522A24201E1Q34183632-D61EAB82-081C-440D-8A34-27BFAF44F09EQ34291736-80D18643-EDB5-4999-A2FF-AAB45DA0A858Q34387852-79EA908B-35A6-4B09-9A1F-4CE2C6146CB9Q34395777-F98FF003-3852-45C8-A11F-4160F23D612EQ34522279-0D5A090B-5167-4BB0-9329-B71D67960850Q34569684-70354DDA-13C5-466C-B4B2-0EEDA67EFAD1Q34778772-A9C0137C-772D-4F9B-8532-88ACBF5D490FQ35137013-8850E966-2F68-4BA5-A9AF-BB2431104775Q35196715-1D401A72-3DE6-4505-8541-BC3ADE0BE9FAQ35210730-B949BB73-FCA4-4411-AF98-45B23345BC35Q35542196-9BB8DCF5-7925-4740-88AC-FDD4D3F4DD98Q35553876-C389702F-37B6-48BB-836C-F22DEE680880Q35569303-DD6B8999-52F6-486F-98F0-392DC1263E4EQ35666129-7FA759AC-33C3-4444-B6AC-4D20240F58CCQ35713138-282B84CA-316E-46F8-B81C-205E75563536Q35786826-EEA618F3-DF75-42D7-8639-9DA56C830597Q35808422-4C5CB338-312C-4460-99B6-93E308871209
P2860
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Phase I clinical trial of the ...... ed prior ketoconazole therapy.
@ast
Phase I clinical trial of the ...... ed prior ketoconazole therapy.
@en
type
label
Phase I clinical trial of the ...... ed prior ketoconazole therapy.
@ast
Phase I clinical trial of the ...... ed prior ketoconazole therapy.
@en
prefLabel
Phase I clinical trial of the ...... ed prior ketoconazole therapy.
@ast
Phase I clinical trial of the ...... ed prior ketoconazole therapy.
@en
P2093
P2860
P921
P356
P1476
Phase I clinical trial of the ...... ved prior ketoconazole therapy
@en
P2093
Arturo Molina
Charles J Ryan
Eric J Small
Gloria Lee
Jennifer Kim
Jonathan E Rosenberg
Lawrence Fong
Matthew R Smith
Thian Kheoh
Vanessa Martins
P2860
P304
P356
10.1200/JCO.2009.24.1281
P407
P577
2010-02-16T00:00:00Z